Angiotensin II receptor / Calcium channel / Thiazide-like diuretic

Class

Triple antihypertensive fixed-dose combination

Notes

Created for AGSAVI (amlodipine/indapamide/valsartan — https://adisinsight.springer.com/drugs/800069890) and AJU-C52 (amlodipine/chlorthalidone/valsartan — https://adisinsight.springer.com/drugs/800065928); researched 2026-08-08

This mechanism describes a three-drug antihypertensive strategy that targets three distinct physiological systems responsible for regulating blood pressure. Angiotensin II receptor blockade interrupts the renin-angiotensin-aldosterone system (RAAS), a hormonal cascade that constricts blood vessels and promotes sodium retention. Calcium channel blockade relaxes vascular smooth muscle directly by preventing calcium influx needed for muscle contraction, reducing peripheral resistance. Thiazide-like diuretics act on the kidney to reduce sodium and water reabsorption, lowering circulating blood volume. Because hypertension often arises from more than one of these mechanisms simultaneously, combining agents that act on the RAAS, vascular tone, and fluid volume can achieve more consistent blood pressure control than any single mechanism alone, particularly in patients whose hypertension is difficult to manage with monotherapy or two-drug regimens. Using three complementary pathways at once also allows each individual component to be dosed lower than it might be alone, which can reduce mechanism-specific side effects while maintaining efficacy. This class of fixed-dose triple combinations is relevant broadly across essential hypertension management, where cardiovascular risk reduction depends on sustained, adequate blood pressure control across diverse patient physiologies and depends on convenient dosing that supports long-term adherence.